Ken Attie

Ken Attie has served as Chief Medical Officer since August 2022. Ken is a pediatric endocrinologist with over 30 years of industry experience as the medical lead in various clinical development programs. This includes over 10 years at Genentech, Inc., where he did laboratory research related to activin effects in the reproductive system and subsequently oversaw the growth hormone clinical and medical affairs programs. This led to approvals of 2 new drug products in five indications. As vice president of medical research at Acceleron Pharma for over 10 years, he led the partnered effort from phase 1 to approval for luspatercept (Reblozyl®), a modified ActRIIB ligand trap, in beta-thalassemia and myelodysplastic syndromes. While at Acceleron, he also investigated the effects of 3 different activin/myostatin pathway drug candidates in 3 neuromuscular diseases. As CMO at Insmed, he led the effort to gain approval of an IGF-1/IGFBP-3 complex (iPlex®) for primary GH insensitivity syndrome. He recently served as CMO at Imara, Inc, with lead indications in sickle cell disease and HFpEF.

Ken obtained his BA degree from University of Michigan and MD and residency at NYU School of Medicine. He was a fellow and assistant clinical professor of pediatric endocrinology at UC-San Francisco Medical Center. He has served as reviewer for numerous endocrine journals, director of the Genentech Endowment for Growth Disorders, and member of the Endocrine Society Corporate Liaison Board.